Mark Freedman profile picture

Contact Information

Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
613 737 8917
mfreedman@ohri.ca

Brenda Barasa
bbarasa@toh.ca

ORCID logo https://orcid.org/0000-0003-1255-9701

Publications

Selected Publications


Atkins H, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny H, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O’Connor P, Ramsay T, Sabloff M, Walker L, and MS Freedman. Immunoablation and Autologous Hematopoietic Stem Cell Rescue Arrests All Measurable Inflammatory Activity and Facilitates Lasting Recovery in Aggressive Multiple Sclerosis. The Lancet 2016 Aug 6;388(10044):576-85.

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.  Lancet. 2016 Mar 12;387(10023):1075-84

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas; Teriflunomide Multiple Sclerosis Oral TEMSO Trial Group and the MRI-AC in Houston Texas. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.  Neurology. 2016 Mar 8;86(10):920-30

Freedman MS.  Are we in need of NEDA? 
Mult Scler. 2016 Jan;22(1):5-6

D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.  Ther Adv Chronic Dis. 2016 Jan;7(1):18-33

Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016 Jan;5:97-104
 
Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in Neurology. 1:20-24. June 2005.

Listings from The Ottawa Hospital Library

This lists the 5 most recent publications in The Ottawa Hospital's Library database from this researcher.This database only starts tracking a researcher's publications once they start working at the Ottawa Hospital Research Institute.
More publications may be available in The Ottawa Hospital Library database.

PubMed Listings

For more publications use this PubMed ID link.